Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Public ClinicalTrials.gov record NCT00550992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin before and after transplant may stop this from happening. It is not yet known which treatment regimen is most effective in treating acute leukemia. PURPOSE: This randomized clinical trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia.
Study identification
- NCT ID
- NCT00550992
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 445 participants
Conditions and interventions
Conditions
Interventions
- anti-thymocyte globulin Biological
- asparaginase Drug
- busulfan Drug
- cyclophosphamide Drug
- cyclosporine Drug
- cytarabine Drug
- daunorubicin hydrochloride Drug
- etoposide Drug
- leucovorin calcium Drug
- melphalan Drug
- mercaptopurine Drug
- methotrexate Drug
- mitoxantrone hydrochloride Drug
- pegaspargase Drug
- prednisolone Drug
- prednisone Drug
- therapeutic hydrocortisone Drug
- thioguanine Drug
- vincristine sulfate Drug
- allogeneic bone marrow transplantation Procedure
- allogeneic hematopoietic stem cell transplantation Procedure
- umbilical cord blood transplantation Procedure
Biological · Drug · Procedure
Eligibility (public fields only)
- Age range
- Up to 1 Year
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2005
- Primary completion
- Nov 30, 2020
- Completion
- Not listed
- Last update posted
- Jul 29, 2019
Started 2006
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Boston | Boston | Massachusetts | 02215 | Recruiting |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | Recruiting |
| M. D. Anderson Cancer Center at University of Texas | Houston | Texas | 77030-4009 | Recruiting |
| Children's Hospital and Regional Medical Center - Seattle | Seattle | Washington | 98105 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00550992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2019 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00550992 live on ClinicalTrials.gov.